Jounce Gets $261m To Start, Milestone Fees Up To $2.3bn In Celgene Deal

A deal with Celgene Corp. worth $261m up front will save Jounce Therapeutics Inc. from having to wade into the treacherous market for initial public offerings in order to advance and accelerate its immuno-oncology research and development programs.